Noxopharm (ASX:NOX) releases DARRT-1 study clinical data

20DecDecember 20, 2019

Noxopharm (ASX:NOX) releases DARRT-1 study clinical data

Clinical drug development company Noxopharm (ASX:NOX) has released DARRT-1 study clinical data.

The Company says the “DARRT program delivers strong anti-cancer response in 47 per cent of men with late-stage prostate cancer”.

An independent oncologist, Professor Paul de Souza, has confirmed the significance of this high response rate.

The company hopes that the “promising new therapy” will meet a “major unmet need in prostate cancer”.

The planned adaptive design Phase 2 study is expected to be the final step before gaining marketing approval.

Shares in Noxopharm (ASX:NOX) are trading 1.61 per cent higher at 32 cents.
Copyright 2019 – Finance News Network

Source: Finance News Network

16JunJune 16, 2020

BetMakers Technology Group (ASX:BET) set to raise $35m to help expand into the US

16 Jun 2020 - BetMakers Technology Group (ASX:BET) is pleased to announce that it has received firm commitments to raise $35 million, before costs, by way of a placement to sophisticated and institutional investors at an offer price of $0.37 per new fully paid ordinary share.

14JanJanuary 14, 2021

Piedmont Lithium (ASX:PLL) boosts management team with 4 new members

14 Jan 2021 - Piedmont Lithium (ASX:PLL) has announced four new appointments to its senior management team as they look to become a domestic producer of lithium hydroxide for the North American battery markets.

09AprApril 9, 2020

HT&E takes 1.8% stake in oOh!media (ASX:OML)

09 Apr 2020 - oOh!media (ASX:OML) has become aware that HT&E has acquired at least 11 million oOh!media shares as at the latest share register obtained by the Company for 6 April 2020, representing at least 1.8 per cent of the Company’s issued capital.